Company Summary - Hikma Pharmaceuticals PLC (LSE:HIK)
732.00p
0.00p
FTSE 250 Pharmaceuticals & BiotechnologyMarket cap: £1,433.476m
NEW Explore our new and improved report for Hikma Pharmaceuticals PLC >>
Gain access to various premium features such as detailed information on financial reports, broker forecasts, directors and shareholders information.
Summary
Development, manufacture and marketing of a broad range of generic and in-licensed pharmaceutical products
| Financials - Interim (25/8/2011) | ||
|---|---|---|
| Turnover | £m | 245.88 |
| Pre-tax Profit | £m | 24.83 |
| EPS | p | 12.30 |
| DPS | p | 4.60 |
| Director | Board Role |
|---|---|
| Samih Darwazah | Chairman |
| Said Darwazah | Chief Executive |
Products Brands & Subsidiaries
Products & Brands
Actos; Amoclan; Blopress; Prograf; Suprax
Subsidiaries
Hikma Pharma SAE; Hikma Farmaceutica SA; Hikma Pharmaceuticals Ltd; Hikma Pharma GmbH; Pharma Ixir Co Ltd...
Broker Sentiment (4 brokers)
Strong SellStrong Buy
| Heading | Date |
|---|---|
| Holding(s) in Company | 02/02/2012 |
| Director Declaration | 01/02/2012 |
| Tender Offer | 17/01/2012 |